Results 31 to 40 of about 205,670 (312)

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges, Kelly A. Duffy, Sara McDonough, Evelyn Kurpiewski, R. Jennifer Randall, Allison Barz Leahy, Haley M. Newman, Joyce P. Lee, Stephen P. Hunger, Anne F. Reilly, David T. Teachey, Susan R. Rheingold, Daniel J. Zheng   +12 more
wiley   +1 more source

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies [PDF]

Journal of Immunotherapy and Precision Oncology
Introduction: Blocking the colony-stimulating factor 1 (CSF-1) signal on tumor-associated macrophages can lead to an upregulation of checkpoint molecules, such as programmed cell death ligand 1 (PD-L1), thus causing resistance to this blockade. Combining
Jibran Ahmed, Bettzy Stephen, Yali Yang, Evan Kwiatkowski, Chinenye Lynette Ejezie, Shubham Pant   +5 more
doaj   +1 more source

ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices): The evolution of a collaborative regional CTSA-funded forum and website for regulatory support

Journal of Clinical and Translational Science, 2021
Availability of trained professionals to assist researchers navigating regulatory pathways for new drug and device development is limited within academic institutions. We created ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices), a
Kimberly A. Brownley, Marie Rape, Amanda Wood, Gaurav Dave, Chad Henderson, Diana Severynse-Stevens, Mike Zmuda, Diane Earp, Carmella Moody, Issis Kelly-Pumarol, Joseph Andrews, Kristen M. Foss, Stephanie Fraser, Erika Segear, Amanda B. Parrish   +14 more
doaj   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Off-label and investigational drugs in the treatment of gambling disorder: a critical review

Frontiers in Pharmacology
Gambling disorder or pathological gambling is a psychiatric disorder with severe and wide-ranging consequences for the affected individual and their surroundings.
Leon Bissig, Jochen Mutschler
doaj   +1 more source

A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma [PDF]

Journal of Immunotherapy and Precision Oncology
Introduction: Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses without inducing
Mohamed A. Gouda, Bettzy Stephen, Yanyan Tian, Anas Alshawa, Dilichukwu O. Chudy Onwugaje, Aya Albittar, Yali Yang, Abdulrazzak Zarifa, Bulent Yilmaz, Serdar Gurses, Ashabari Sprenger, Mohamed H. Derbala, Amanda Brink, Jeffrey Andrew How, Justin Moyers, Sarina A. Piha-Paul, David S. Hong, Funda Meric-Bernstam, Sapna P. Patel, Isabella Glitza Oliva   +19 more
doaj   +1 more source

Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial [PDF]

Background: The use of oral flutamide is rarely investigated in acne therapy. The aim of this study was to compare the efficacy of oral flutamide with that of a cyproterone-estradiol combination in treating acne lesions.
عدالتخواه, حسن, پورفرضی, فرهاد, صادقی, همایون   +2 more
core   +1 more source

Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA) [PDF]

, 2010
<p><b>Background and Purpose:</b> Thrombolysis for acute ischemic stroke in patients aged >80 years is not approved in some countries due to limited trial data in the very elderly.
Bluhmki, E., Diener, H.-C., Lees, K.R., Lyden, P.D., Mishra, N.K.   +4 more
core   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

The value of source data verification in a cancer clinical trial [PDF]

, 2012
Background Source data verification (SDV) is a resource intensive method of quality assurance frequently used in clinical trials. There is no empirical evidence to suggest that SDV would impact on comparative treatment effect results from a clinical ...
AS Therasse P, BW Morrison, C Baigent, Catrin Tudur Smith, David Cunningham, Deborah D. Stocken, EL Eisenstein, GS Buyse M, JA Lane, Janet Dunn, JL Lienard, John P. Neoptolemos, Paula Ghaneh, S Funning, Salomon M. Stemmer, Trevor Cox, VJ Favalli G   +16 more
core   +2 more sources